A Safety and Tolerability of PSD502 (a Topical Anesthetic) in the Treatment of Premature Ejaculation
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
A phase I, single-center, double-blind, randomized, placebo-controlled, safety and
pharmacokinetic study to evaluate systemic and local vaginal exposure to lidocaine and
prilocaine and the metabolites, 2,6-dimethylaniline (2,6-DMA) and o-toluidine, in female
healthy volunteer subjects following daily application of 60 mg PSD502 or placebo to the
vagina and cervix for seven days